Literature DB >> 18283560

Tumor histology helps to identify Lynch syndrome among colorectal cancer patients.

Brindusa Truta1, Yunn-Yi Chen, Amie M Blanco, Guoren Deng, Peggy G Conrad, Yong Ho Kim, Eun Taek Park, Sanjay Kakar, Young S Kim, Fernando Velayos, Marvin H Sleisenger, Jonathan P Terdiman.   

Abstract

OBJECTIVE: To determine the value of histology in identifying Lynch syndrome among those patients with early onset of colorectal cancer (CRC).
METHODS: Demographic, clinical and cancer history data from patients diagnosed with CRC before 60 years of age, and treated at our institution between 1997 and 2005, were collected from medical records and direct interview. Their tumors were assessed to identify histological features suggestive of high frequency microsatellite instability (MSI-H): tumor infiltrating lymphocytes, Crohn's like inflammatory reaction, mucinous, signet ring cells, medullary growth pattern and then, tested for microsatellite instability (MSI) and MLH1/ MSH2 protein expression.
RESULTS: Sixty-five patients were included in the study. The mean age at diagnosis was 48 +/- 9.9 years. Overall, 28 (43%) patients, including 13 of 35 diagnosed between ages 50 and 60, had tumor demonstrating one or more histological features suggestive of MSI-H. These patients were younger (45 vs. 50 years, P = 0.02) and more commonly had family history of Lynch syndrome-related cancers (36 vs. 19%), though the latter feature did not reach statistical significance (P = 0.07). Eleven of 25 tumors with MSI-H histology, but only 1 of 29 tumors without special histological features were found to be MSI-H (P < 0.0001). Histology had a positive predictive value of 44% and a negative predictive value of 97% for identifying MSI-H tumors.
CONCLUSIONS: Limiting MSI analysis only to those tumors with suggestive histology would have reduced the need for testing by nearly 60% of all tumors from patients that met the revised Bethesda guidelines.

Entities:  

Mesh:

Year:  2008        PMID: 18283560     DOI: 10.1007/s10689-008-9186-8

Source DB:  PubMed          Journal:  Fam Cancer        ISSN: 1389-9600            Impact factor:   2.375


  27 in total

1.  MSH2 genomic deletions are a frequent cause of HNPCC.

Authors:  J Wijnen; H van der Klift; H Vasen; P M Khan; F Menko; C Tops; H Meijers Heijboer; D Lindhout; P Møller; R Fodde
Journal:  Nat Genet       Date:  1998-12       Impact factor: 38.330

Review 2.  Testing for defective DNA mismatch repair in colorectal carcinoma: a practical guide.

Authors:  Lawrence J Burgart
Journal:  Arch Pathol Lab Med       Date:  2005-11       Impact factor: 5.534

3.  Features of colorectal cancers with high-level microsatellite instability occurring in familial and sporadic settings: parallel pathways of tumorigenesis.

Authors:  J Young; L A Simms; K G Biden; C Wynter; V Whitehall; R Karamatic; J George; J Goldblatt; I Walpole; S A Robin; M M Borten; R Stitz; J Searle; D McKeone; L Fraser; D R Purdie; K Podger; R Price; R Buttenshaw; M D Walsh; M Barker; B A Leggett; J R Jass
Journal:  Am J Pathol       Date:  2001-12       Impact factor: 4.307

4.  Prediction of MLH1 and MSH2 mutations in Lynch syndrome.

Authors:  Judith Balmaña; David H Stockwell; Ewout W Steyerberg; Elena M Stoffel; Amie M Deffenbaugh; Julia E Reid; Brian Ward; Thomas Scholl; Brant Hendrickson; John Tazelaar; Lynn Anne Burbidge; Sapna Syngal
Journal:  JAMA       Date:  2006-09-27       Impact factor: 56.272

5.  Lynch syndrome (hereditary nonpolyposis colorectal cancer) diagnostics.

Authors:  Kristina Lagerstedt Robinson; Tao Liu; Jana Vandrovcova; Britta Halvarsson; Mark Clendenning; Thierry Frebourg; Nickolas Papadopoulos; Kenneth W Kinzler; Bert Vogelstein; Päivi Peltomäki; Richard D Kolodner; Mef Nilbert; Annika Lindblom
Journal:  J Natl Cancer Inst       Date:  2007-02-21       Impact factor: 13.506

6.  Clinical and pathological characteristics of sporadic colorectal carcinomas with DNA replication errors in microsatellite sequences.

Authors:  H Kim; J Jen; B Vogelstein; S R Hamilton
Journal:  Am J Pathol       Date:  1994-07       Impact factor: 4.307

7.  BRAF mutation is frequently present in sporadic colorectal cancer with methylated hMLH1, but not in hereditary nonpolyposis colorectal cancer.

Authors:  Guoren Deng; Ian Bell; Suzanne Crawley; James Gum; Jonathan P Terdiman; Brian A Allen; Brindusa Truta; Marvin H Sleisenger; Young S Kim
Journal:  Clin Cancer Res       Date:  2004-01-01       Impact factor: 12.531

8.  Histopathology and mismatch repair status of 458 consecutive colorectal carcinomas.

Authors:  Cheryl L Wright; Ian D Stewart
Journal:  Am J Surg Pathol       Date:  2003-11       Impact factor: 6.394

9.  Pathology features in Bethesda guidelines predict colorectal cancer microsatellite instability: a population-based study.

Authors:  Mark A Jenkins; Shinichi Hayashi; Anne-Marie O'Shea; Lawrence J Burgart; Tom C Smyrk; David Shimizu; Paul M Waring; Andrew R Ruszkiewicz; Aaron F Pollett; Mark Redston; Melissa A Barker; John A Baron; Graham R Casey; James G Dowty; Graham G Giles; Paul Limburg; Polly Newcomb; Joanne P Young; Michael D Walsh; Stephen N Thibodeau; Noralane M Lindor; Loïc Lemarchand; Steven Gallinger; Robert W Haile; John D Potter; John L Hopper; Jeremy R Jass
Journal:  Gastroenterology       Date:  2007-04-25       Impact factor: 22.682

10.  Evaluation of microsatellite instability and immunohistochemistry for the prediction of germ-line MSH2 and MLH1 mutations in hereditary nonpolyposis colon cancer families.

Authors:  Siobhan S Wahlberg; James Schmeits; George Thomas; Massimo Loda; Judy Garber; Sapna Syngal; Richard D Kolodner; Edward Fox
Journal:  Cancer Res       Date:  2002-06-15       Impact factor: 12.701

View more
  7 in total

1.  Can a gastrointestinal pathologist identify microsatellite instability in colorectal cancer with reproducibility and a high degree of specificity?

Authors:  Eli Brazowski; Paul Rozen; Sara Pel; Ziona Samuel; Irit Solar; Guy Rosner
Journal:  Fam Cancer       Date:  2012-06       Impact factor: 2.375

2.  Bethesda criteria for microsatellite instability testing: impact on the detection of new cases of Lynch syndrome.

Authors:  Miguel Serrano; Pedro Lage; Sara Belga; Bruno Filipe; Inês Francisco; Paula Rodrigues; Ricardo Fonseca; Paula Chaves; Isabel Claro; Cristina Albuquerque; António Dias Pereira
Journal:  Fam Cancer       Date:  2012-12       Impact factor: 2.375

3.  Defective DNA Mismatch Repair Influences Expression of Endometrial Carcinoma Biomarkers.

Authors:  Ekene I Okoye; Amanda S Bruegl; Bryan Fellman; Rajyalakshmi Luthra; Russell R Broaddus
Journal:  Int J Gynecol Pathol       Date:  2016-01       Impact factor: 2.762

4.  Proficiency of DNA repair genes and microsatellite instability in operated colorectal cancer patients with clinical suspicion of lynch syndrome.

Authors:  Isabella Nicácio de Freitas; Fábio Guilherm Caserta Maryssael de Campos; Venâncio Avancini Ferreira Alves; Juliana Magalhães Cavalcante; Dirce Carraro; Renata de Almeida Coudry; Márcio Augusto Diniz; Sérgio Carlos Nahas; Ulysses Ribeiro
Journal:  J Gastrointest Oncol       Date:  2015-12

5.  Identification of patients at-risk for Lynch syndrome in a hospital-based colorectal surgery clinic.

Authors:  Patrícia Koehler-Santos; Patricia Izetti; Jamile Abud; Carlos Eduardo Pitroski; Silvia Liliana Cossio; Suzi Alves Camey; Cláudio Tarta; Daniel C Damin; Paulo Carvalho Contu; Mario Antonello Rosito; Patricia Ashton-Prolla; João Carlos Prolla
Journal:  World J Gastroenterol       Date:  2011-02-14       Impact factor: 5.742

Review 6.  Lynch Syndrome: Its Impact on Urothelial Carcinoma.

Authors:  Andrea Katharina Lindner; Gert Schachtner; Gennadi Tulchiner; Martin Thurnher; Gerold Untergasser; Peter Obrist; Iris Pipp; Fabian Steinkohl; Wolfgang Horninger; Zoran Culig; Renate Pichler
Journal:  Int J Mol Sci       Date:  2021-01-07       Impact factor: 5.923

Review 7.  A review on the molecular diagnostics of Lynch syndrome: a central role for the pathology laboratory.

Authors:  Margot G F van Lier; Anja Wagner; Monique E van Leerdam; Katharina Biermann; Ernst J Kuipers; Ewout W Steyerberg; Hendrikus Jan Dubbink; Winand N M Dinjens
Journal:  J Cell Mol Med       Date:  2009-11-19       Impact factor: 5.310

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.